Abstract
Colorectal cancer (CRC) is a serious complication of inflammatory bowel disease (IBD). Although conclusive evidence is still missing, epidemiological and preliminary clinical work strongly suggests that mesalazine may have chemopreventive properties against IBD-related CRC. Therefore, in recent years, several experimental studies have been conducted to dissect the mechanism(s) by which mesalazine interferes with CRC cell growth and survival. This review summarizes the current information on the molecular pathways that are regulated by mesalazine in CRC.
Keywords: Colorectal cancer (CRC), inflammatory bowel disease (IBD), mesalazine, molecular pathways, EGFR
Current Cancer Therapy Reviews
Title: Molecular Targets of Mesalazine in Colorectal Cancer
Volume: 4 Issue: 4
Author(s): Carmine Stolfi, Roberto Pellegrini, Francesco Pallone and Giovanni Monteleone
Affiliation:
Keywords: Colorectal cancer (CRC), inflammatory bowel disease (IBD), mesalazine, molecular pathways, EGFR
Abstract: Colorectal cancer (CRC) is a serious complication of inflammatory bowel disease (IBD). Although conclusive evidence is still missing, epidemiological and preliminary clinical work strongly suggests that mesalazine may have chemopreventive properties against IBD-related CRC. Therefore, in recent years, several experimental studies have been conducted to dissect the mechanism(s) by which mesalazine interferes with CRC cell growth and survival. This review summarizes the current information on the molecular pathways that are regulated by mesalazine in CRC.
Export Options
About this article
Cite this article as:
Stolfi Carmine, Pellegrini Roberto, Pallone Francesco and Monteleone Giovanni, Molecular Targets of Mesalazine in Colorectal Cancer, Current Cancer Therapy Reviews 2008; 4 (4) . https://dx.doi.org/10.2174/157339408786413326
DOI https://dx.doi.org/10.2174/157339408786413326 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008
Anti-Cancer Agents in Medicinal Chemistry Perspectives in Biomolecular Therapeutic Intervention in Cancer: From the Early to the New Strategies With Type I Interferons
Current Medicinal Chemistry Role of Aberrant Lipid Metabolism of Cancer Stem Cells in Cancer Progression
Current Cancer Drug Targets The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
Current Cancer Drug Targets Farnesylated Proteins as Anticancer Drug Targets: From Laboratory to the Clinic
Current Medicinal Chemistry - Anti-Cancer Agents Treatment Directed to Signalling Molecules in Patients with Advanced Differentiated Thyroid Cancer
Anti-Cancer Agents in Medicinal Chemistry Efficacy and Safety of Bevacizumab in Glioblastomas
Current Medicinal Chemistry The Metabolic Syndrome and Chronic Liver Disease
Current Pharmaceutical Design Plant Defensins and Defensin-Like Peptides - Biological Activities and Biotechnological Applications
Current Pharmaceutical Design Advances in the Researches on the Biological Activities and Inhibitors of Phosphatidylinositol 3-kinase
Anti-Cancer Agents in Medicinal Chemistry Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research Antiangiogenic Resistance: Novel Angiogenesis Axes Uncovered by Antiangiogenic Therapies Research
Current Drug Targets New Cathepsin D Inhibitor Library Utilizing Hydroxyethyl Isosteres with Cyclic Tertiary Amines
Medicinal Chemistry Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus
Current Cancer Drug Targets Polynucleotide Kinase as a Potential Target for Enhancing Cytotoxicity by Ionizing Radiation and Topoisomerase I Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Effects of Limonoid Cedrelone on MDA-MB-231 Breast Tumor Cells in vitro
Anti-Cancer Agents in Medicinal Chemistry Vascular Endothelial Growth Factor (VEGF) Inhibition - A Critical Review
Anti-Cancer Agents in Medicinal Chemistry Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets Incorporation of Targeted Agents in the Management of Patients with Advanced Gastric Cancer
Current Medicinal Chemistry Is Metformin a Therapeutic Paradigm for Colorectal Cancer: Insight into the Molecular Pathway?
Current Drug Targets